Seminars in Nephrology
Volume 25, Issue 1 , Pages 50-55 , January 2005

Uric acid and transplantation

  • Marilda Mazzali

      Affiliations

    • Division of Nephrology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, UNICAMP, Campinas-SP, Brazil.
    • Corresponding Author InformationAddress reprint requests to Marilda Mazzali, MD, Disciplina de Nefrologia- DCM/FCM Unicamp, Rua Tessália Vieira de Camargo, 126, Cidade Universitária Zeferino Vaz, Campinas-SP, CEP 13083-970, Brazil.

References 

  1. Clive DM . Renal transplant associated hyperuricemia and gout . J Am Soc Nephrol . 2000;11:974–979
  2. Ahn KJ , Kim YS , Lee HC , et al.   Cyclosporine induced hyperuricemia after renal transplant (Clinical characteristics and mechanisms) . Transplant Proc . 1992;24:1391–1392
  3. Lin HY , Rocher LL , McQuillan MA , et al.   Cyclosporine induced hyperuricemia and gout . N Engl J Med . 1989;321:287–292
  4. Delaney V , Sumrani N , Daskalakis P , et al.   Hyperuricemia and gout in renal transplant recipients . Transplant Proc . 1992;24:1773–1774
  5. Neal DAJ , Tom BDM , Gimson AES , et al.   Hyperuricemia, gout and renal function after liver transplantation . Transplantation . 2001;72:1689–1691
  6. Taillander J , Allemanni M , Liote F , et al.   Serum uric acid and liver transplantation . Transplant Proc . 1995;27:2189
  7. Burack DA , Griffith BP , Thompson ME , et al.   Hyperuricemia and gout among heart transplant recipients receiving cyclosporine . Am J Med . 1992;92:141–146
  8. West C , Carpenter BJ , Hakala TR . The incidence of gout in renal transplant recipients . Am J Kidney Dis . 1987;10:369–371
  9. Noordzij TC , Leunissen KM , Van Hooff JP . Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use . Transplantation . 1991;52:64–67
  10. Better OS . Tubular dysfunction following kidney transplantation . Nephron . 1980;25:209–213
  11. Marcén R , Gallego N , Orofino L , et al.   Impairment of tubular secretion of urate in renal transplant patients on cyclosporine . Nephron . 1995;70:307
  12. Hansen JM , Fogh Andersen N , et al.   Glomerular and tubular function in renal transplant patients treated with and without cyclosporin A . Nephron . 1998;80:450–457
  13. Gores PF , Fryd DS , Sutherland DER , et al.   Hyperuricemia after renal transplantation . Am J Surg . 1988;156:397–400
  14. Ellion GB . The pharmacology of azathioprine . Ann N Y Acad Sci . 1993;685:401–407
  15. Cummings D , Sekar M , Halil O , et al.   Myelosuppression associated with azathioprine allopurinol interaction after heart and lung transplantation . Transplantation . 1996;61:1661–1662
  16. Venkat RG , Sharman VL , Lee HÁ . Azathioprine and allopurinol (A potentially dangerous combination) . J Intern Med . 1990;228:69–71
  17. Navascues RA , Gomez E , Rodriguez M , et al.   Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients . Nephron . 2002;91:173–174
  18. Jacobs F , Manzer M , Bruneel F , et al.   Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant patients with gout . Transplantation . 1997;64:1087–1088
  19. Bennett WM , De Mattos A , Meyer MM , et al.   Chronic cyclosporine nephropathy. The Achilles’ heel of immunosuppressive therapy . Kidney Int . 1996;50:1098
  20. Laine J , Holmberg C . Mechanisms of hyperuricemia in cyclosporine treated renal transplanted children . Nephron . 1996;74:318
  21. Zurcher RM , Bock HA , Thiel G . Hyperuricemia in cyclosporine treated patients (A GFR effect) . Nephrol Dial Transplant . 1996;11:153
  22. Ochiai T , Ishibashi M , Fukao K , et al.   Japanese multicenter studies of FK506 in renal transplantation . Transplant Proc . 1995;27:50–52
  23. Pilmore HL , Faire B , Dittmer I . Tacrolimus for treatment of gout in renal transplantation . Transplantation . 2001;72:1703–1705
  24. The Sirolimus European Renal Transplant Study Charpentier B . Bicêtre Hospital Experience with sirolimus based therapy in human renal transplantation: The Sirolimus European Renal Transplant Study . Transplant Proc . 2003;35(suppl A):58S–61S
  25. Sirolimus European Renal Transplant Study Group Morales JM , Wramner L , Kreis H , et al.   Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients . Am J Transplant . 2002;2:436–442
  26. Mazzali M , Kanellis J , Han L , et al.   Hyperuricemia induces a primary arteriolopathy in the rats by a blood pressure independent mechanism . Am J Physiol . 2002;282:F991
  27. Aker S , Ivens K , Grabensee B , et al.   Cardiovascular risk factors and diseases after renal transplantation . Int J Urol Nephrol . 1998;30:777–788
  28. Dimeny EM . Cardiovascular disease after renal transplantation . Kidney Int Suppl . 2002;80:S78–S84
  29. Gerhardt U , Grobe Huttmann M , Hohage H . Influence of hyperglycemia and hyperuricemia on long term transplant survival in kidney transplant patients . Clin Transplant . 1999;13:375–379
  30. Mazzali M , Kim YG , Suga S , et al.   Hyperuricemia exacerbates chronic cyclosporine nephropathy . Transplantation . 2001;71:900–905
  31. Sanchez-Lozada LG , Tapia E , Avila-Casado C , et al.   Mild hyperuricemia induces glomerular hypertension in the rat . Am J Physiol . 2002;283:F1105–F1110
  32. Sabbatini M , De Nicola L , Samsone G , et al.   Renal hypoperfusion as the primary cause of cyclosporine induced nephropathy . Nephrol Dial Transplant . 1993;8:794–797
  33. Mazzali M , Hughes J , Kim YG , et al.   Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism . Hypertension . 2001;38:1101–1106
  34. Pichler RH , Franceschini N , Young BA , et al.   Pathogenesis of cyclosporine nephropathy (Roles of angiotensin II and osteopontin) . J Am Soc Nephrol . 1995;6:1186–1196
  35. Burdmann EA , Andoh TF , Nast CC , et al.   Prevention of experimental cyclosporine induced interstitial fibrosis by losartan and enalapril . Am J Physiol . 1995;269:F491–F499
  36. Young BA , Burdmann EA , Johnson RJ , et al.   Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy . Kidney Int . 1995;48:431–438
  37. Ojo AO , Held PJ , Port FK , et al.   Chronic renal failure after transplantation of a non renal organ . N Engl J Med . 2003;349:931–940
  38. Moreno JM , Cuervas-Mons V , Rubio E , et al.   Chronic renal dysfunction after liver transplantation in adult patients (Prevalence, risk factors and impact on mortality) . Transplant Proc . 2003;35:1907–1908
  39. Oliveras A , Roquer J , Puig JM , et al.   Stroke in renal transplant recipients (Epidemiology, predictive risk factors and outcome) . Clin Transplant . 2003;17:1–8
  40. Perez-Ruiz F , Gomez-Ullate P , Amenabar JJ , et al.   Long term efficacy of hyperuricemia treatment in renal transplant patients . Nephrol Dial Transplant . 2003;18:603–606
  41. Johnson RJ , Rideout BA . Uric acid and diet- insights into the epidemic of cardiovascular disease . N Engl J Med . 2004;350:1071–1073
  42. the Rapamune Maintenance Regimen Trial Kreis H , Oberbauer R , Campistol JP . Long term benefits with sirolimus based therapy after early cyclosporine withdrawal . J Am Soc Nephrol . 2004;15:809–817
  43. Tedoriya T , Keogh AM , Kusano K , et al.   Reversal of chronic cyclosporine nephrotoxicity after heart transplantation. Potential role of mycophenolate mofetil . J Heart Lung Transplant . 2002;21:976–982
  44. Mazzali M , Quadros KRS , Santos RLS , et al.   Calcineurin inhibitor withdrawal in renal transplant recipients. Improvement in renal function and reduction of cardiovascular risk . J Am Soc Nephrol . 2003;14:650A; (abstract)
  45. Li C , Yang CW , Kim WY , et al.   Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine . Am J Physiol . 2003;284:F389–F398
  46. Baryalei M , Zenker D , Pieske B , et al.   Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low dose cyclosporine . Transplant Proc . 2003;35:1539–1542
  47. Saunders RN , Bicknell GR , Nicholson ML . The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular and histological markers of chronic allograft nephropathy . Transplantation . 2003;75:772–780
  48. Flechner SM , Goldfarb D , Modlin C , et al.   Kidney transplantation without calcineurin inhibitor drugs (A prospective, randomized trial of sirolimus versus cyclosporine) . Transplantation . 2002;74:1070–1076
  49. Burnier M , Roch Ramel F , Brunner HR . Renal effects of angiotensin II receptor blockade in normotensive subjects . Kidney Int . 1996;49:1787
  50. Minghelli G , Seydoux C , Goy JJ , et al.   Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients . Transplantation . 1998;66:268–271
  51. Kamper AL , Nielsen AH . Uricosuric effect of losartan in patients with renal transplants . Transplantation . 2001;72:671–674
  52. Reyes AJ . Cardiovascular drugs and serum uric acid . Cardiovasc Drug Ther . 2003;17:397–414
  53. Schmidt A , Gruber U , Bohmig G , et al.   The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CSA . Nephrol Dial Transplant . 2001;16:1034–1037
  54. Nakashima M , Uematsu T , Kosuge K , et al.   Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist in healthy subjects . Eur J Clin Pharmacol . 1992;42:333–335
  55. Chanard J , Toupance O , Lavaud S , et al.   Amlodipine reduces cyclosporine induced hyperuricemia in hypertensive renal transplant recipients . Nephrol Dial Transplant . 2003;18:2147–2153
  56. Zurcher RM , Bock HA , Thiel G . Excellent uricosuric efficacy of benzbromarone in cyclosporine A treated renal transplant patients (A prospective study) . Nephrol Dial Transplant . 1994;9:548–551
  57. Dupont P , Hunt I , Goldberg L , et al.   Colchicine myoneuropathy in a renal transplant patient . Transplant Int . 2002;15:374–376
  58. Ducloux D , Schuller V , Bressson Vautrin C , et al.   Colchicine myopathy in renal transplant recipients on cyclosporine . Nephrol Dial Transplant . 1997;12:2389–2392
  59. Elisaf M . Effects of fibrates on serum metabolic parameters . Curr Med Res Opin . 2002;18:269–276
  60. Takahashi S , Moriwaki Y , Yamamoto T , et al.   Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism . Ann Rheum Dis . 2003;62:572–575
  61. Wierzbicki AS , Mikhailidis DP , Wray R , et al.   Statin-fibrate combination therapy for hyperlipidemia (a review) . Curr Med Res Opin . 2003;19:155–168
  62. Lipscombe J , Lewis GF , Cattran D , et al.   Deterioration in renal function associated with fibrate therapy . Clin Nephrol . 2001;55:39–44
  63. Johnson RJ , Kivlighn SD , Kim YG , et al.   Reapprasial of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease and renal disease . Am J Kidney Dis . 1999;33:225–234
  64. Johnson RJ , Kang DH , Feig D , et al.   Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? . Hypertension . 2003;41:1183–1190
  65. Nakagawa T , Mazzali M , Kang DH , et al.   Hyperuricemia causes glomerular hypertrophy in the rat . Am J Nephrol . 2003;23:2–7
  66. Howard RJ , Patton PR , Reed AI , et al.   The changing causes of graft loss and death after kidney transplantation . Transplantation . 2002;73:1923–1928

PII: S0270-9295(04)00151-2

doi: 10.1016/j.semnephrol.2004.09.008

Seminars in Nephrology
Volume 25, Issue 1 , Pages 50-55 , January 2005

Article Tools